GANX · Insider Trading
Gain Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by GANX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Gwen A Melincoff | Director | A | +25,000 deriv. | — |
| 2026-07-17 | Hans Peter Hasler | Director | A | +25,000 deriv. | — |
| 2026-07-17 | Jeffrey Scott Riley | Director | A | +25,000 deriv. | — |
| 2026-07-17 | Khalid Islam | Director | A | +25,000 deriv. | — |
| 2026-07-17 | Claude Nicaise | Director | A | +25,000 deriv. | — |
| 2026-07-17 | Dov A Md Goldstein | Director | A | +25,000 deriv. | — |
| 2026-03-26 | Gene Mack | CEO, President | A | +200,000 deriv. | — |
| 2026-03-26 | Gianluca Fuggetta | See Remark | A | +50,000 deriv. | — |
| 2025-06-25 | Hans Peter Hasler | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Dov A Md Goldstein | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Jeffrey Scott Riley | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Gwen A Melincoff | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Claude Nicaise | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Eric I Richman | Director | A | +15,000 deriv. | — |
| 2025-06-25 | Khalid Islam | Director | A | +15,000 deriv. | — |
| 2025-03-21 | Gene Mack | CEO, President | A | +200,000 deriv. | — |
| 2025-03-21 | Gianluca Fuggetta | See Remark | A | +50,000 deriv. | — |
| 2025-01-07 | Gene Mack | CEO, President | A | +271,325 deriv. | — |
| 2024-08-12 | Gene Mack | CFO and Interim CEO | Buy | +14,400 | +$14.54K |
| 2024-08-12 | Khalid Islam | Executive Chairman | Buy | +50,000 | +$49.94K |
| 2024-07-01 | Eric I Richman | Director | Buy | +17,000 | +$20.67K |
| 2024-06-26 | Gwen A Melincoff | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Claude Nicaise | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Eric I Richman | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Hans Peter Hasler | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Dov A Md Goldstein | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Khalid Islam | Director | A | +15,000 deriv. | — |
| 2024-06-26 | Jeffrey Scott Riley | Director | A | +15,000 deriv. | — |
| 2024-04-08 | Gene Mack | Chief Financial Officer | A | +200,000 deriv. | — |
| 2024-04-01 | Jeffrey Scott Riley | Director | Buy | +30,000 | +$115.77K |
| 2024-03-28 | Matthias Alder | Chief Executive Officer | MIXED | +14,127 | −$24.71K |
| 2024-03-25 | Gianluca Fuggetta | See Remark | A | +50,000 deriv. | — |
| 2024-03-25 | Matthias Alder | Chief Executive Officer | A | +370,000 deriv. | — |
| 2023-12-22 | Matthias Alder | Chief Executive Officer | MIXED | +431 | −$507 |
| 2023-12-14 | Matthias Alder | Chief Executive Officer | Sell | −1,820 | −$4.55K |
| 2023-10-03 | Matthias Alder | Chief Executive Officer | M | +825 | — |
| 2023-09-22 | Matthias Alder | Chief Executive Officer | M | +2,550 | — |
| 2023-09-22 | Eric I Richman | Director | M | +54,900 | — |
| 2023-07-05 | Matthias Alder | Chief Executive Officer | M | +3,300 | — |
| 2023-06-26 | Khalid Islam | Director | A | +10,500 deriv. | — |
| 2023-06-26 | Dov A Md Goldstein | Director | A | +10,500 deriv. | — |
| 2023-06-26 | Jeffrey Scott Riley | Director | A | +10,500 deriv. | — |
| 2023-06-26 | Hans Peter Hasler | Director | A | +10,500 deriv. | — |
| 2023-06-26 | Gwen A Melincoff | Director | A | +10,500 deriv. | — |
| 2023-06-26 | Claude Nicaise | Director | A | +10,500 deriv. | — |
| 2023-04-12 | Charles Evan Ballantyne | Chief Financial Officer | A | +150,000 deriv. | — |
| 2023-03-27 | Gianluca Fuggetta | Principal Accounting Officer | A | +15,000 deriv. | — |
| 2023-03-27 | Salvatore Calabrese | Chief Financial Officer | A | +75,000 deriv. | — |
| 2023-03-27 | Matthias Alder | Chief Executive Officer | A | +225,000 deriv. | — |
| 2022-09-22 | Hans Peter Hasler | Director | A | +10,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Khalid Islam | Executive Chairman | 930,784 | $1.07M |
| Eric I Richman | Director | 292,458 | $336.33K |
| Jeffrey Scott Riley | Director | 30,000 | $34.50K |
| Gene Mack | CEO, President | 14,400 | $16.56K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GANX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.